Her principal research activities consist of designing and conducting clinical trials that test investigational new drugs in the treatment of breast cancer. She has specific expertise in the use of epigenetic modifiers in breast cancer patients, and in developing both tissue and imaging-based biomarkers of response to breast cancer therapies. She is the Principal Investigator for a number of multicenter trials in collaboration with the Cancer Therapy Evaluation Program (CTEP) at the NCI, the Translational Breast Cancer Research Consortium (TBCRC), and the Eastern Co-operative Oncology Group (ECOG)-ACRIN.